Taewoong Choi

Overview:

Based on my prior experience in basic/translational immunology research and clinical hematopoietic stem cell transplantation, I am interested in early phase clinical protocols for novel immunotherapy of hematologic malignancies.

Positions:

Assistant Professor of Medicine

Medicine, Hematologic Malignancies and Cellular Therapy
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

M.D. 2002

Seoul National University

Internship and Residency in Internal Medicine

St. Luke's Memorial Hospital Center

Hematology/Oncology Fellowship

University of Pittsburgh School of Medicine

BMT Fellowship

Stanford University School of Medicine

Postdoctoral Research Fellow on T32 Training Grant

Stanford University School of Medicine

Grants:

JZP395-201

Administered By
Duke Cancer Institute
Role
Principal Investigator
Start Date
End Date

NKTR 255

Administered By
Duke Cancer Institute
Role
Principal Investigator
Start Date
End Date

Publications:

Cognitive Impairment in Candidates for Allogeneic Hematopoietic Stem Cell Transplantation

Authors
Smith, PJ; Lew, M; Lowder, YP; Romero, K; Thompson, J; Bohannen, L; Pittman, A; Sullivan, K; Choi, T; Gasparetto, C; Horwitz, ME; Long, GD; Lopez, R; Rizzieri, DA; Sarantopoulos, S; Chao, NJ; Sung, AD
MLA Citation
Smith, Patrick J., et al. “Cognitive Impairment in Candidates for Allogeneic Hematopoietic Stem Cell Transplantation.” Biology of Blood and Marrow Transplantation, vol. 26, no. 3, ELSEVIER SCIENCE INC, 2020, pp. S241–S241.
URI
https://scholars.duke.edu/individual/pub1434721
Source
wos
Published In
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
Volume
26
Published Date
Start Page
S241
End Page
S241

Clinical and Neuroimaging Predictors of Post-Transplant Delirium

Authors
MLA Citation
Smith, Patrick J., et al. “Clinical and Neuroimaging Predictors of Post-Transplant Delirium.” Biology of Blood and Marrow Transplantation, vol. 26, no. 3, ELSEVIER SCIENCE INC, 2020, pp. S119–S119.
URI
https://scholars.duke.edu/individual/pub1434723
Source
wos
Published In
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
Volume
26
Published Date
Start Page
S119
End Page
S119

Phase II Trial of Pasireotide to Prevent GI Toxicity and Acute Gvhd in Allogeneic HSCT

Authors
Ramalingam, S; Siamakpour-Reihani, S; Bohannon, L; Ren, Y; Sibley, A; Nixon, A; Lyu, J; Xie, J; Choi, T; Gasparetto, C; Horwitz, ME; Long, GD; Lopez, R; Rizzieri, DA; Sarantopoulos, S; Chao, NJ; Sung, AD
MLA Citation
Ramalingam, Sendhilnathan, et al. “Phase II Trial of Pasireotide to Prevent GI Toxicity and Acute Gvhd in Allogeneic HSCT.” Biology of Blood and Marrow Transplantation, vol. 26, no. 3, ELSEVIER SCIENCE INC, 2020, pp. S48–49.
URI
https://scholars.duke.edu/individual/pub1434724
Source
wos
Published In
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
Volume
26
Published Date
Start Page
S48
End Page
S49

Is autologous stem cell transplantation still relevant for multiple myeloma?

PURPOSE OF REVIEW: Autologous stem cell transplantation has been the standard of care in myeloma treatment for many years, but the availability of newer antimyeloma drugs and the emerging data from chimeric antigen receptor (CAR) T-cell clinical studies make us question the relevance of it. The purpose of this review is to go over recent data and to reassess the current status of autologous stem cell transplantation as a standard of care. RECENT FINDINGS: Autologous stem cell transplantation can be safely performed for elderly patients and there is no absolute age limit. Recent data on BEAM (Carmustine, Etoposide, Cytarabine, and Melphalan), Busulfan/Melphalan, and Carmustine/Melphalan conditioning when compared with Melphalan showed favorable survival outcomes with manageable toxicities although we need to see data from randomized, multicenter studies. Posttransplant maintenance and consolidation can maximize the benefit of transplant by prolonging progression-free survival. Current B-cell maturation antigen CAR T-cell therapy showed remarkably high response rates, but didn't seem to provide durable response yet. SUMMARY: Recent advances in myeloma therapy and autologous stem cell transplantation are described. Although we've seen many new developments including CAR T-cell therapies, autologous stem cell transplantation remains as the standard of care. However, it may be replaced by or combined with newer therapies in the future.
Authors
MLA Citation
Choi, Taewoong. “Is autologous stem cell transplantation still relevant for multiple myeloma?Curr Opin Hematol, vol. 26, no. 6, Nov. 2019, pp. 386–91. Pubmed, doi:10.1097/MOH.0000000000000538.
URI
https://scholars.duke.edu/individual/pub1411540
PMID
31567432
Source
pubmed
Published In
Curr Opin Hematol
Volume
26
Published Date
Start Page
386
End Page
391
DOI
10.1097/MOH.0000000000000538

RE: Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma

Authors
Diwakar, D; Choi, T; Tawbi, TH; Kirkwood, JM
MLA Citation
Diwakar, D., et al. “RE: Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma.” Annals of Oncology, vol. 25, no. 8, Elsevier BV, Aug. 2014, pp. 1670–71. Crossref, doi:10.1093/annonc/mdu196.
URI
https://scholars.duke.edu/individual/pub1271144
Source
crossref
Published In
Annals of Oncology
Volume
25
Published Date
Start Page
1670
End Page
1671
DOI
10.1093/annonc/mdu196

Research Areas:

Cellular therapy
Immunotherapy
Multiple Myeloma
Plasma cell diseases
Stem Cell Transplantation